Home >> Research Area >>Neuroscience>>COX>> (S)-(+)-Ibuprofen

(S)-(+)-Ibuprofen

Cyclooxygenase inhibitor (COX-1 > COX-2) CAS# 51146-56-6

(S)-(+)-Ibuprofen

Catalog No. BCC4042----Order now to get a substantial discount!

Product Name & Size Price Stock
(S)-(+)-Ibuprofen: 5mg $6 In Stock
(S)-(+)-Ibuprofen: 10mg Please Inquire In Stock
(S)-(+)-Ibuprofen: 20mg Please Inquire Please Inquire
(S)-(+)-Ibuprofen: 50mg Please Inquire Please Inquire
(S)-(+)-Ibuprofen: 100mg Please Inquire Please Inquire
(S)-(+)-Ibuprofen: 200mg Please Inquire Please Inquire
(S)-(+)-Ibuprofen: 500mg Please Inquire Please Inquire
(S)-(+)-Ibuprofen: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of (S)-(+)-Ibuprofen

Number of papers citing our products

Chemical structure

(S)-(+)-Ibuprofen

3D structure

Chemical Properties of (S)-(+)-Ibuprofen

Cas No. 51146-56-6 SDF Download SDF
PubChem ID 39912 Appearance Powder
Formula C13H18O2 M.Wt 206.28
Type of Compound N/A Storage Desiccate at -20°C
Synonyms (S)-Ibuprofen
Solubility DMSO : 100 mg/mL (484.78 mM; Need ultrasonic)
Ethanol : 100 mg/mL (484.78 mM; Need ultrasonic)
H2O : 1 mg/mL (4.85 mM; Need ultrasonic and warming)
Chemical Name (2S)-2-[4-(2-methylpropyl)phenyl]propanoic acid
SMILES CC(C)CC1=CC=C(C=C1)C(C)C(=O)O
Standard InChIKey HEFNNWSXXWATRW-JTQLQIEISA-N
Standard InChI InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)/t10-/m0/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of (S)-(+)-Ibuprofen

DescriptionNon-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase 1 and cyclooxygenase 2 (IC50 values are 12 and 80 μM respectively). Active isomer of ibuprofen.

(S)-(+)-Ibuprofen Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

(S)-(+)-Ibuprofen Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of (S)-(+)-Ibuprofen

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 4.8478 mL 24.2389 mL 48.4778 mL 96.9556 mL 121.1945 mL
5 mM 0.9696 mL 4.8478 mL 9.6956 mL 19.3911 mL 24.2389 mL
10 mM 0.4848 mL 2.4239 mL 4.8478 mL 9.6956 mL 12.1194 mL
50 mM 0.097 mL 0.4848 mL 0.9696 mL 1.9391 mL 2.4239 mL
100 mM 0.0485 mL 0.2424 mL 0.4848 mL 0.9696 mL 1.2119 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on (S)-(+)-Ibuprofen

S(+)-Ibuprofen is capable of inhibiting cyclooxygenase (COX) at clinically relevant concentrations, R(-)-ibuprofen is not a COX inhibitor.

Featured Products
New Products
 

References on (S)-(+)-Ibuprofen

S(+)-ibuprofen destabilizes MYC/MYCN and AKT, increases p53 expression, and induces unfolded protein response and favorable phenotype in neuroblastoma cell lines.[Pubmed:24173829]

Int J Oncol. 2014 Jan;44(1):35-43.

Neuroblastoma is a common pediatric solid tumor that exhibits a striking clinical bipolarity: favorable and unfavorable. The survival rate of children with unfavorable neuroblastoma remains low among all childhood cancers. MYCN and MYC play a crucial role in determining the malignancy of unfavorable neuroblastomas, whereas high-level expression of the favorable neuroblastoma genes is associated with a good disease outcome and confers growth suppression of neuroblastoma cells. A small fraction of neuroblastomas harbors TP53 mutations at diagnosis, but a higher proportion of the relapse cases acquire TP53 mutations. In this study, we investigated the effect of S(+)-ibuprofen on neuroblastoma cell lines, focusing on the expression of the MYCN, MYC, AKT, p53 proteins and the favorable neuroblastoma genes in vitro as biomarkers of malignancy. Treatment of neuroblastoma cell lines with S(+)-ibuprofen resulted in a significant growth suppression. This growth effect was accompanied by a marked decrease in the expression of MYC, MYCN, AKT and an increase in p53 expression in neuroblastoma cell lines without TP53 mutation. In addition, S(+)-ibuprofen enhanced the expression of some favorable neuroblastoma genes (EPHB6, CD44) and genes involved in growth suppression and differentiation (EGR1, EPHA2, NRG1 and SEL1L). Gene expression profile and Ingenuity pathway analyses using TP53-mutated SKNAS cells further revealed that S(+)-ibuprofen suppressed molecular pathways associated with cell growth and conversely enhanced those of cell cycle arrest and the unfolded protein response. Collectively, these results suggest that S(+)-ibuprofen or its related compounds may have the potential for therapeutic and/or palliative use for unfavorable neuroblastoma.

Impact of patent ductus arteriosus and subsequent therapy with ibuprofen on the release of S-100B and oxidative stress index in preterm infants.[Pubmed:25542161]

Med Sci Monit. 2014 Dec 26;20:2799-805.

BACKGROUND: Hemodynamically significant patent ductus arteriosus (hsPDA) leads to injury in tissues/organs by reducing perfusion of organs and causing oxidative stress. The purpose of this study was to evaluate the oxidant/antioxidant status in preterm infants with hsPDA by measuring the total antioxidant capacity and total oxidant status and to assess neuronal damage due to oxidant stress related to hsPDA. MATERIAL AND METHODS: This prospective study included 37 low-birth-weight infants with echocardiographically diagnosed hsPDA treated with oral ibuprofen and a control group of 40 infants without PDA. Blood samples were taken from all infants, and than the total antioxidant capacity (TAC), total oxidant status (TOS), and S-100B protein levels were assessed and oxidative stress index was calculated before and after therapy. RESULTS: The mean pre-therapy TOS level and oxidative stress index (OSI) value of the patients with hsPDA were significantly higher, but TAC level was lower than in the control group. There were no statistically significant differences in the mean post-therapy values of TOS, TAC, OSI, and S-100B protein between the two groups. CONCLUSIONS: hsPDA may cause cellular injury by increasing oxidative stress and damaging tissue perfusion; however the brain can compensate for oxidative stress and impaired tissue perfusion through well-developed autoregulation systems to decrease tissue injury.

In vitro evaluation of S-(+)-ibuprofen as drug candidate for intra-articular drug delivery system.[Pubmed:24168233]

Drug Dev Ind Pharm. 2015 Jan;41(1):85-94.

Intra-articular drug delivery systems (DDSs) are envisaged as interesting alternative to locally release non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen to reduce pain in patients with osteoarthritis. The present study examines the efficacy of S-(+)-ibuprofen on cartilage degradation as drug candidate for DDS loading. Humeral cartilage and joint capsule explants were collected from healthy sheep shoulder joints and they were cultured in mono- or in co-culture for 13 days with LPS in combination with S-(+)-ibuprofen at 50 microM and 1 mM. S-(+)-ibuprofen (50 microM) blocked prostaglandins production in LPS-activated explants but did not reduce cartilage degradation. By contrast, 1 mM S-(+)-ibuprofen treatment of cartilage explants reduced nitric oxide synthesis by 51% (p = 0.0072), proteoglycans degradation by 35% (p = 0.0114) and expression of serum amyloid protein - the main protein induced upon LPS challenge - by 44% (p < 0.0001). On contrary, in presence of synovial membrane, the protective effects of S-(+)-ibuprofen on cartilage damages were significantly diminished. At 1mM, S-(+)-ibuprofen reduced the cell lysis during culture of cartilage and joint capsule either in mono- or in co-culture. This study performed on sheep explants shows that 1 mM S-(+)-ibuprofen inhibited cartilage degradation via a mechanism independent of cyclooxygenase inhibition. Reduction of prostaglandins synthesis at 50 microM in all treatment groups and reduction of cartilage degradation observed at 1 mM suggest that S-(+)-ibuprofen could be considered as a promising drug candidate for the loading of intra-articular DDS.

Two Enzyme Cooperatively Catalyzed Tandem Polymerization for the Synthesis of Polyester Containing Chiral (R)- or (S)-Ibuprofen Pendants.[Pubmed:25200738]

Macromol Rapid Commun. 2014 Sep 8.

An interesting cooperation between Candida antarctica Lipase B (CAL-B) and alkaline protease from Bacillus subtilis (BSP) in the copolymerization of bulky ibuprofen-containing hydroxyacid methyl ester (HAEP) and epsilon-caprolactone (epsilon-CL) is observed. This cooperation improved the M n of the polymers from 3130 (CAL-B) to 9200 g mol(-1) (CAL-B/BSP). Experimental results clearly indicate that CAL-B mainly catalyzes the ring-opening polymerization (ROP) of epsilon-CL under the initiation of HAEP to form the homopolymer of epsilon-CL, while BSP catalyzes the subsequent polycondensation of the ROP product to yield the copolymer with increased molecular weight. Furthermore, using suitable chemo-enzymatic methods, valuable polyesters with chiral (R)- or (S)-ibuprofen pendants can be tailor-made.

Description

(S)-(+)-Ibuprofen is the S(+)-enantiomer of Ibuprofen that inhibits COX-1 and COX-2 activity with IC50s of 2.1 μM and 1.6 μM. (S)-(+)-Ibuprofen has analgesic, antiinflammatory and antipyretic effects.

Keywords:

(S)-(+)-Ibuprofen,51146-56-6,(S)-Ibuprofen,Natural Products,COX, buy (S)-(+)-Ibuprofen , (S)-(+)-Ibuprofen supplier , purchase (S)-(+)-Ibuprofen , (S)-(+)-Ibuprofen cost , (S)-(+)-Ibuprofen manufacturer , order (S)-(+)-Ibuprofen , high purity (S)-(+)-Ibuprofen

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: